Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0549 | 0.5458 | 0.5458 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0941 | 0.982 | 0.9706 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.0957 | 1 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0957 | 1 | 1 |
Brugia malayi | MH2 domain containing protein | 0.014 | 0.0913 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0941 | 0.982 | 0.982 |
Mycobacterium ulcerans | hypothetical protein | 0.0565 | 0.5637 | 0.5 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.0565 | 0.5637 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0957 | 1 | 1 |
Schistosoma mansoni | 6-phosphofructokinase | 0.0957 | 1 | 1 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.0565 | 0.5637 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0565 | 0.5637 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0957 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.0941 | 0.982 | 0.9706 |
Giardia lamblia | Hypothetical protein | 0.0565 | 0.5637 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0957 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.0941 | 0.982 | 0.9706 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.014 | 0.0913 | 0.0913 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.0941 | 0.982 | 0.9706 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0957 | 1 | 1 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.014 | 0.0913 | 0.0913 |
Onchocerca volvulus | 0.0957 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.